Case Report
Can Cell Bound Complement Activation Products Predict Inherited Complement Deficiency in Systemic Lupus Erythematosus?
| | ANA | Result | Reference ranges |
| | Immunofluorescence (IIF) | 1 : 5120 (positive)/homogeneous | Negative (<1 : 80); positive (≥1 : 80) |
| | Analyte | Result | Reference ranges |
| | Anti-dsDNA (ELISA) | 581 IU/mL (positive, confirmed by Crithidia) | ≤301 (negative); > 301 (positive) | | Anti-Smith (ELISA) | 46 U/mL (positive) | <5 (negative); 5–10 (equivocal); > 10 (positive) | | EC4d (FACS) | 6 Net MFI (negative) | ≤12 (negative); > 12–75 (positive); > 75 (strong
positive) | | BC4d (FACS) | 34 Net MFI (negative) | ≤48 (negative); > 48–200 (positive); > 200 (Strong Positive) | | Anti-U1RNP IgG | 13 U/ml (positive) | <5 negative; 5–10 equivocal; > 10 positive | | Anti-RNP70 IgG | 1 U/ml (negative) | <7 negative; 7–10 equivocal; > 10 positive | | Anti-SS-A/Ro IgG | 182 U/ml (positive) | <7 negative; 7–10 equivocal; > 10 positive | | Anti-SS-B/La IgG | >320 U/ml (positive) | <7 negative; 7–10 equivocal; > 10 positive | | Anti-C1q IgG | 144 U/ml (positive) | <20 units (negative); ≥ 20 units (positive) | | C3 | 53 mg/dl | 90–180 mg/dl | | C4 | 3 mg/dl | 16–47 mg/dl |
|
|
